Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel R Morales

Showing results (61-70 of 112) with videos related to

Pageof 12
Sort By:
European Journal of Public Health|August 19, 2025
An extension of the Benefit Risk Assessment of VaccinEs toolkit to evaluate Comirnaty and Spikevax vaccination in the European UnionNeilshan Loedy, Hector G Dorta, Steven Abrams, et al.
The British Journal of General Practice : the Journal of the Royal College of General Practitioners|March 30, 2023
Age, sex, and socioeconomic differences in multimorbidity measured in four ways: UK primary care cross-sectional analysisClare MacRae, Stewart W Mercer, David Henderson, et al.
BMJ (Clinical Research Ed.)|July 24, 2024
Estimating the economic effect of harm associated with high risk prescribing of oral non-steroidal anti-inflammatory drugs in England: population based cohort and economic modelling studyElizabeth M Camacho, Leonie S Penner, Amy Taylor, et al.
The Lancet. Digital Health|April 9, 2025
Utilising the Benefit Risk Assessment of Vaccines (BRAVE) toolkit to evaluate the benefits and risks of Vaxzevria in the EU: a population-based studyHector Gonzalez Dorta, Johan Verbeeck, Jonas Crevecoeur, et al.
Journal of Biomedical Informatics|August 12, 2025
Corrigendum to "A pipeline for harmonising NHS Scotland laboratory data to enable national-level analyses". [J. Biomed. Inform. 162 (2025) 104771]Chuang Gao, Shahzad Mumtaz, Sophie McCall, et al.
The Lancet. Healthy Longevity|August 5, 2023
Antipsychotic drug prescribing and mortality in people with dementia before and during the COVID-19 pandemic: a retrospective cohort study in Wales, UKChristian Schnier, Aoife McCarthy, Daniel R Morales, et al.
Communications Medicine|July 8, 2025
Robustly measuring multimorbidity using disparate linked datasetsRegina Prigge, Kelly J Fleetwood, Caroline A Jackson, et al.
Journal of Biomedical Informatics|January 4, 2025
A pipeline for harmonising NHS Scotland laboratory data to enable national-level analysesChuang Gao, Shahzad Mumtaz, Sophie McCall, et al.
Plos Medicine|April 4, 2023
The impact of varying the number and selection of conditions on estimated multimorbidity prevalence: A cross-sectional study using a large, primary care population datasetClare MacRae, Megan McMinn, Stewart W Mercer, et al.
Plos Medicine|September 11, 2025
Correction: Depression and physical multimorbidity: A cohort study of physical health condition accrual in UK BiobankKelly J Fleetwood, Bruce Guthrie, Caroline A Jackson, et al.
Pageof 12

Showing results (61-70 of 112) with videos related to

Sort By:
Pageof 12
European Journal of Public Health|August 19, 2025
An extension of the Benefit Risk Assessment of VaccinEs toolkit to evaluate Comirnaty and Spikevax vaccination in the European UnionNeilshan Loedy, Hector G Dorta, Steven Abrams, et al.
The British Journal of General Practice : the Journal of the Royal College of General Practitioners|March 30, 2023
Age, sex, and socioeconomic differences in multimorbidity measured in four ways: UK primary care cross-sectional analysisClare MacRae, Stewart W Mercer, David Henderson, et al.
BMJ (Clinical Research Ed.)|July 24, 2024
Estimating the economic effect of harm associated with high risk prescribing of oral non-steroidal anti-inflammatory drugs in England: population based cohort and economic modelling studyElizabeth M Camacho, Leonie S Penner, Amy Taylor, et al.
The Lancet. Digital Health|April 9, 2025
Utilising the Benefit Risk Assessment of Vaccines (BRAVE) toolkit to evaluate the benefits and risks of Vaxzevria in the EU: a population-based studyHector Gonzalez Dorta, Johan Verbeeck, Jonas Crevecoeur, et al.
Journal of Biomedical Informatics|August 12, 2025
Corrigendum to "A pipeline for harmonising NHS Scotland laboratory data to enable national-level analyses". [J. Biomed. Inform. 162 (2025) 104771]Chuang Gao, Shahzad Mumtaz, Sophie McCall, et al.
The Lancet. Healthy Longevity|August 5, 2023
Antipsychotic drug prescribing and mortality in people with dementia before and during the COVID-19 pandemic: a retrospective cohort study in Wales, UKChristian Schnier, Aoife McCarthy, Daniel R Morales, et al.
Communications Medicine|July 8, 2025
Robustly measuring multimorbidity using disparate linked datasetsRegina Prigge, Kelly J Fleetwood, Caroline A Jackson, et al.
Journal of Biomedical Informatics|January 4, 2025
A pipeline for harmonising NHS Scotland laboratory data to enable national-level analysesChuang Gao, Shahzad Mumtaz, Sophie McCall, et al.
Plos Medicine|April 4, 2023
The impact of varying the number and selection of conditions on estimated multimorbidity prevalence: A cross-sectional study using a large, primary care population datasetClare MacRae, Megan McMinn, Stewart W Mercer, et al.
Plos Medicine|September 11, 2025
Correction: Depression and physical multimorbidity: A cohort study of physical health condition accrual in UK BiobankKelly J Fleetwood, Bruce Guthrie, Caroline A Jackson, et al.
Pageof 12